Strides Pharma Science has filed a comprehensive regulatory disclosure under SEBI Regulation 30 regarding its strategic $12 million acquisition of branded generic pharmaceutical products from Sandoz across Sub-Saharan Africa. The formal disclosure, submitted to BSE and NSE on March 17, 2026, provides detailed transaction parameters and corporate guarantee arrangements for the deal announced earlier.

Transaction Structure and Parties

The acquisition involves multiple entities within the Strides group structure, with specific roles defined for regulatory compliance:

Portfolio Coverage and Market Impact

The transaction encompasses four key markets where Strides maintains established operations: Western Sahara (10 countries), Ghana, Nigeria, and Kenya. The portfolio includes multiple established brands across anti-infective, cardiovascular, and dermatology therapeutic segments, with several products individually recording annual sales exceeding $1 million.

The integration is expected to position Strides among the top five pharmaceutical companies in the Sub-Saharan Africa region by sales, and among the top two within its represented markets. The deal structure includes both fully acquired products and select products that Strides will continue to market through in-licensing arrangements.

Corporate Guarantee Framework

As part of the transaction structure, Strides Pharma Global Pte. Limited will provide corporate guarantees to Sandoz securing SPIAG's payment obligations:

Regulatory and Compliance Aspects

The disclosure confirms that the transaction with Sandoz does not constitute a related party transaction, with promoter groups having no interest in the deal. However, inter-company transactions between SPIAG and SPG are classified as related party transactions conducted at arm's length.

The transaction remains subject to customary closing conditions, including antitrust filings in applicable jurisdictions. Expected completion is targeted for the end of Q2 FY27 (September 30, 2026), with the arrangement also providing for yearly royalty payments based on a percentage of net sales for Distribution Products.

Strategic Alignment

The formal regulatory filing reinforces the strategic importance of this acquisition to Strides' 'in Africa for Africa' strategy. The transaction is designed to enhance market reach across key SSA markets, strengthen therapeutic leadership, and unlock cross-selling opportunities through deeper penetration of prescriber bases, pharmacies, clinics, and healthcare institutions.

Strides Pharma Science Limited has successfully completed the acquisition of the remaining 50% equity stake in Neviton Softech Private Limited through its wholly owned subsidiary Arco Lab Private Limited. The transaction was finalized on February 16, 2026, transforming Neviton into a wholly owned subsidiary of Arco Lab.

Transaction Details

The acquisition involved the purchase of 5,560 equity shares representing the remaining 50% stake in Neviton from Universal Alloy Corporation Design S.R.L, a Romanian company. The transaction was executed through cash consideration.

Acquisition Timeline and Background

This acquisition represents the final phase of Arco Lab's strategic investment in Neviton. The subsidiary had previously acquired a 25% equity stake in August 2022, followed by an additional 25% stake in January 2024. With the current transaction, Arco Lab now holds 100% ownership of Neviton.

About Neviton Softech

Neviton Softech Private Limited, incorporated on February 25, 2010, operates in the IT services and engineering solutions sector. The company specializes in developing machine interfaces through IoT devices and integrating live data feeds into real-time applications. Neviton maintains operational presence in both India and USA.

Financial Performance

Neviton's financial metrics for FY25 demonstrate solid operational performance:

Three-Year Revenue Trend

Strategic Rationale

Arco Lab Private Limited was established to provide business services in driving business and IT transformation, cost efficiencies, and operational excellence, serving as a Global Life Science Capability Centre. The subsidiary also offers IT infrastructure services, enterprise application services, manufacturing IT services, new technologies, and cybersecurity services.

The acquisition enables synergies between Neviton and Arco Lab, allowing the combined entity to offer enhanced knowledge-based and IT services. This integration is expected to deliver higher scale, scope, and significant cash savings while enabling better internal group-wise digitization processes.

Regulatory Compliance

The transaction was disclosed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. No governmental or regulatory approvals were required for the acquisition. The company confirmed that none of the promoters or promoter group of Strides Pharma Science Limited have any interest in the transaction.